OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: _______ to _______ Commission File Number: 001-32288 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2023 NEPHROS, INC. (Exact name of registrant as specified in its charter) DELAWARE 13-3971809 (State or o ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: _______ to _______ Commission File Number: 001-32288 NEPHROS, INC. Indicate by check mark whether the registrant: (1) has filed all reports required to be fil ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2023 DELAWARE 13-3971809 (State or other jurisdiction of incorporation or organization) 380 Lackawanna Place South Orange, NJ 07079 (Address of principal executive offices) (Zip Code) (201) 343-5202 Registrant's telephone number, including area code OR ☐ TRANSITION REPORT PURSUANT TO SEC ...

Financial Performance - Total net revenues for the fiscal year ended December 31, 2022, were $9.975 million, a decrease of 2% from $10.217 million in 2021[169] - Gross margin for the fiscal year ended December 31, 2022, was approximately 47%, down from 55% in 2021, reflecting an 8% decrease due to increased shipping costs and inventory reserves[171] - Net loss attributable to Nephros, Inc. shareholders for the fiscal year ended December 31, 2022, was $7.382 million, an increase of 80% from $4.107 million in 2021[169] - Loss from discontinued operations was approximately $2.8 million for the year ended December 31, 2022, compared to $1.1 million in 2021, primarily due to asset impairment[180] - The company incurred a net loss of $3.2 million for the year ended December 31, 2022[187] Expenses - Research and development expenses decreased by 16% to $1.255 million in 2022, primarily due to reduced investment in the Water Filtration segment[172] - Selling, general and administrative expenses increased by 6% to $7.593 million in 2022, attributed to higher sales headcount and associated costs[174] Cash Flow and Liquidity - Cash and cash equivalents decreased to $3.634 million as of December 31, 2022, down from $6.973 million in 2021[181] - The accumulated deficit as of December 31, 2022, was $142.8 million, with expectations of incurring additional operating losses until profitability is achieved[183] - Net cash used in operating activities increased to $3.2 million for the year ended December 31, 2022, compared to $1.4 million in 2021, an increase of $1.8 million[187] - Net cash provided by financing activities was approximately $43,000 for the year ended December 31, 2022, primarily from proceeds of $0.2 million from warrant exercises[189] - The company believes that existing cash resources and anticipated revenue will be sufficient to fund operations for at least the next 12 months[185] - Future liquidity sources will depend on the development, marketing, and sales of water filtration products[186] Operational Changes - The company plans to wind down Specialty Renal Products, Inc. operations and liquidate its assets due to limited capital and lack of strategic partnerships[162] - The company may need to reduce discretionary expenditures, including headcount and R&D spending, if demand for products decreases[185] Purchase Commitments - The company has agreed to make minimum annual aggregate purchases from Medica of €3.5 million (approximately $3.7 million) for the year ended December 31, 2022[191] - Aggregate purchase commitments for the year ended December 31, 2022, totaled €3.2 million (approximately $3.4 million)[191] - The company has a commitment to make up a €0.3 million purchase shortfall based on anticipated future revenues[191] Segment Performance - Total net revenues in the Water Filtration segment decreased by 2% in the year ended December 31, 2022[169] - Net cash used in investing activities remained stable at $0.1 million for both years ended December 31, 2022, and 2021[188]

Nephros, Inc. (NASDAQ:NEPH) Q4 2022 Earnings Conference Call March 8, 2023 4:30 PM ET Company Participants Kirin Smith - PCG Advisory Andrew Astor - President and CEO Conference Call Participants Anthony Vendetti - Maxim Group Joseph Schuler - JAS Investors Operator Good afternoon, and welcome to the Nephros Inc. Fourth Quarter 2022 Financial Results Conference Call. [Operator Instructions] Please note, this event is being recorded. I would now like to turn the conference over to Kirin Smith, Investor Relat ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: _______ to _______ Commission File Number: 001-32288 NEPHROS, INC. (Exact name of registrant as specified in its charter) DELAWARE 13-3971809 (State or o ...

Nephros, Inc. (NASDAQ:NEPH) Q3 2022 Earnings Conference Call November 2, 2022 4:30 PM ET Company Participants Kirin Smith - PCG Advisory Andrew Astor - President and CEO Conference Call Participants Marc Wiesenberger - B. Riley Securities Paul Resnik - Resnik Asset Management Operator Good day, everyone, and welcome to the Nephros, Inc. Third Quarter 2022 Financial Results Conference Call. [Operator Instructions]. At this time, I'd like to turn the floor over to Kirin Smith with PCG Advisory. Please go ahea ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (State or other jurisdiction of incorporation or organization) 380 Lackawanna Place South Orange, NJ 07079 (Address of principal executive offices) (Zip Code) (201) 343-5202 Registrant's tel ...

Nephros, Inc. (NASDAQ:NEPH) Q2 2022 Earnings Conference Call August 10, 2022 4:30 PM ET Company Participants Stephanie Prince - PCG Advisory, IR Andy Astor - President and CEO Conference Call Participants Marc Wiesenberger - B. Riley FBR Ralph Weil - R. Weil Investment Management Neil Cataldi - Blueprint Capital Operator Good afternoon. And welcome to the Nephros Incorporated Second Quarter 2022 Financial Results Conference Call. All participants will be in listen-only mode. [Operator Instructions] After to ...

Nephros, Inc. (NASDAQ:NEPH) Q1 2022 Earnings Conference Call May 4, 2022 4:30 PM ET Company Participants Kirin Smith - President, PCG Advisory Andy Astor - President and Chief Executive Officer Wes Lobo - Chief Commercial Officer Conference Call Participants Anthony Vendetti - Maxim Group Sahil Kazmi - B. Riley Securities Operator Good day and welcome to the Nephros, Inc. First Quarter 2022 Financial Results Conference Call. All participants will be in a listen-only mode. [Operator Instructions] Please not ...